Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Critical Care | Nursing | Oncology | Pharmacy | Surgery | Journal

Back to Journal Articles

Anticoagulation Therapy Appears to Be Safe After TAVI

Last Updated: November 01, 2012.

 

No increased risk of bleeding or other adverse outcome after receiving anticoagulant therapy

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
After transcatheter aortic valve implantation there is no increased risk of bleeding or other adverse outcomes for those patients who have an indication for anticoagulant therapy, according to a study published online Oct. 29 in The American Journal of Cardiology.

THURSDAY, Nov. 1 (HealthDay News) -- After transcatheter aortic valve implantation (TAVI) there is no increased risk of bleeding or other adverse outcomes for those patients who have an indication for anticoagulant therapy, according to a study published online Oct. 29 in The American Journal of Cardiology.

Filippo Figini, M.D., of the S. Raffaele Scientific Institute in Milan, and colleagues conducted a retrospective study using data from 360 patients who had undergone TAVI to examine the best antithrombotic approach. Anticoagulant therapy was indicated for 16.7 percent of participants, primarily due to atrial fibrillation. After clinical evaluation of thrombotic and hemorrhagic risk, 72 percent of these patients were discharged with warfarin plus a single antiplatelet drug. Their outcomes were compared to those of the 300 patients with no indication for anticoagulant therapy who were treated with dual antiplatelet therapy.

The researchers found that, during a median of 11 months of follow up, 15 percent of the study population died, and mortality did not correlate with antithrombotic regimen. The incidence of cerebral events (4.6 percent) and intracranial hemorrhage (1.1 percent) was low and was not significantly different between the groups. The bleeding rate was also similar between the groups.

"When anticoagulation is indicated after TAVI, many variables must be taken into account. The most frequent scenario in this study was patients in atrial fibrillation, most of whom were discharged with warfarin plus a single antiplatelet medication. When bleeding was a concern, especially in the absence of coronary disease, warfarin alone was prescribed," the authors write. "These results suggest that this approach is safe, but data from larger, randomized studies are needed."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Self-Management of Low Back Pain Has Small Effects Next: Optimal Delivery Time for Twins Is 38 Weeks or Later

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.